카바페넴 내성 장내세균목(CRE) 감염증 : 시장 인사이트, 역학 및 시장 예측(2036년)

Carbapenem-resistant Enterobacteriaceae (CRE) Infection Insights and Trends

• According to DelveInsight's analysis, the CRE infection market size was found to be ~USD 300 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• A significant proportion of CRE infections is linked to comorbidities such as diabetes, chronic kidney disease, cancer, and immunosuppressive conditions, particularly among critically ill hospitalized patients, highlighting the need for early diagnosis, infection control, antimicrobial stewardship, and targeted treatment strategies to reduce mortality and limit resistance spread.
• In the CRE infection market across the 7MM, advanced B-lactam/B-lactamase inhibitor combinations such as ZERBAXA, RECARBRIO, and VABOMERE hold a substantial share of the treatment landscape, supported by their growing use in managing multidrug-resistant Gram-negative infections.
• The current CRE infection treatment market is characterized by continued reliance on older low-cost agents such as polymyxins, tigecycline, aminoglycosides, and carbapenem-based combination regimens, alongside a growing shift toward premium novel antibiotics including FETROJA, XACDURO, and ZAYNICH, driven by the need for improved efficacy, reduced resistance development, and better safety outcomes in severe CRE infections.
• The CRE infection treatment landscape is driven by a mix of established and novel antibacterial therapies, with products such as RECARBRIO, VABOMERE, and ZAYNICH reflecting continued innovation aimed at overcoming carbapenem resistance, improving patient outcomes, and advancing antimicrobial stewardship.
• While the CRE infection pipeline remains relatively limited, several novel anti-infective candidates, including Zidebactam/Cefepime, Cefepime/Tazobactam, and Zidebactam/Ertapenem, are in clinical development. These therapies aim to address the significant unmet need in multidrug-resistant Enterobacteriaceae infections by enhancing activity against carbapenem-resistant pathogens and reducing reliance on polymyxin-based treatments.

DelveInsight's 'Carbapenem-resistant Enterobacteriaceae (CRE) Infection- Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the CRE, historical and forecasted epidemiology, as well as the CRE infection market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The CRE infection market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates CRE infection patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in CRE infection and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Carbapenem-resistant Enterobacteriaceae (CRE) Infection Market

Rising CRE Infection Incidence

The increasing incidence of CRE, particularly among children 1-5 years of age, is the primary driver of CRE market expansion.

Rising Opportunities in Novel CRE Infection Therapies

Growing antimicrobial resistance and the limited efficacy of existing antibiotics are creating opportunities for developers of novel targeted therapies for CRE infections.

Emerging CRE Infection Competitive Landscape

Emerging therapies such as WCK 5222, WCK 4282, and WCK 6777 aim to address critical unmet needs in CRE by offering improved activity against carbapenem-resistant pathogens, reducing reliance on toxic legacy antibiotics, and expanding treatment options for multidrug-resistant infections.

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Understanding and Treatment Algorithm

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Overview

Carbapenem-Resistant Enterobacteriaceae Infection is a serious and often life-threatening bacterial infection caused by Enterobacteriaceae resistant to carbapenem antibiotics, primarily affecting hospitalized and immunocompromised patients. These infections commonly involve the bloodstream, lungs, urinary tract, and wounds, and are driven by factors such as antibiotic overuse, prolonged healthcare exposure, invasive medical procedures, and transmission within healthcare settings.

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Diagnosis

Carbapenem-Resistant Enterobacteriaceae Infection is diagnosed through clinical assessment, microbiological culture, and antimicrobial susceptibility testing to identify carbapenem-resistant organisms. Common specimens include blood, urine, respiratory secretions, and wound samples. Molecular diagnostic methods, such as PCR, may be used to detect carbapenemase genes, including KPC, NDM, OXA-48, VIM, and IMP. Additional laboratory and imaging studies are often performed to determine the source, extent, and severity of infection.

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Treatment

The primary goals of CRE infection treatment are to eradicate resistant pathogens, control severe infections, reduce mortality, and prevent further antimicrobial resistance and transmission. Management is mainly pharmacologic and guided by susceptibility testing. Novel B-lactam/B-lactamase inhibitor combinations such as ceftazidime-avibactam (AVYCAZ/ZAVICEFTA), meropenem-vaborbactam (VABOMERE), and imipenem-cilastatin-relebactam (RECARBRIO) are commonly used first-line therapies for susceptible CRE infections. In metallo-B-lactamase-producing strains, combination therapies such as aztreonam with ceftazidime-avibactam or newer agents like cefepime-zidebactam (Zaynich) may be considered. Additional agents, including plazomicin (ZEMDRI), tigecycline, and polymyxins, are used in complicated or refractory cases. Supportive strategies such as source control, infection prevention, and antimicrobial stewardship are essential to improve outcomes and limit the spread of CRE infections.

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Unmet Needs

The section "unmet needs of CRE Infection" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Limited availability of effective antibiotics against multidrug-resistant CRE strains

2. Rising antimicrobial resistance leading to reduced treatment success rates

3. Need for rapid and accurate diagnostic tools for early detection

4. High mortality and recurrence rates, especially in critically ill patients, and others.....

Comprehensive unmet needs insights in Carbapenem-resistant Enterobacteriaceae (CRE) Infection and their strategic implications are provided in the full report.

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Epidemiology

Key Findings from Carbapenem-resistant Enterobacteriaceae (CRE) Infection Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, the total incident cases of CRE infection in the 7MM were approximately 23,000 in 2025.
• The US, in 2025, accounted for around 14,000 incident cases of CRE infection, which will increase by the year 2036.
• Among the EU4, Italy accounted for the highest number of incident cases of CRE infection, followed by France, whereas Germany accounted for the lowest number of cases in 2025.
• In 2025, there were approximately 350 cases of CRE infections in Japan, which will increase by 2036.
• Males represent approximately 60% of all reported CRE Infection cases.

Carbapenem-resistant Enterobacteriaceae (CRE) Infection Drug Chapters & Competitive Analysis

The CRE infection drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the CRE infection treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the CRE infection therapeutics market.

Approved Therapies for Carbapenem-resistant Enterobacteriaceae (CRE) Infection

Meropenem/Vaborbactam (VABOMERE): Deerfield Management Company

VABOMERE is an intravenous combination therapy comprising the carbapenem antibiotic meropenem and the novel B-lactamase inhibitor vaborbactam. Approved by the US FDA in 2017, it is indicated for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. VABOMERE has demonstrated strong activity against CRE, particularly Klebsiella pneumoniae carbapenemase (KPC)-producing strains. By inhibiting serine carbapenemases, vaborbactam restores the antibacterial activity of meropenem against resistant Gram-negative pathogens. Its development represents a significant advancement in addressing the growing threat of multidrug-resistant bacterial infections and the need for novel antimicrobial treatment options.

Plazomicin (ZEMDRI): Cipla

ZEMDRI is a next-generation intravenous aminoglycoside antibiotic developed for the treatment of multidrug-resistant Gram-negative infections, particularly CRE. Originally developed by Achaogen, Inc., it received US FDA approval in 2018 for cUTIs in adults with limited treatment options. Designed to overcome common aminoglycoside resistance mechanisms, plazomicin demonstrates strong activity against resistant pathogens such as Klebsiella pneumoniae and Escherichia coli, supporting its role in addressing critical antimicrobial resistance challenges.

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Pipeline Analysis

Zidebactam/Cefepime (WCK-5222): Wockhardt

WCK 5222, developed by Wockhardt Ltd., is an investigational intravenous antibiotic combination comprising cefepime and the novel B-lactamase inhibitor zidebactam. The therapy is being developed for the treatment of multidrug-resistant Gram-negative infections, including CRE Infection. By enhancing cefepime activity against resistant pathogens, WCK 5222 aims to provide a carbapenem-sparing treatment option for severe hospital-acquired infections and address the growing challenge of antimicrobial resistance.

Cefepime/Tazobactam (WCK-4282): Wockhardt

WCK-4282, developed by Wockhardt Ltd., is an investigational intravenous B-lactam/B-lactamase inhibitor combination comprising cefepime and tazobactam. The therapy is being developed for the treatment of multidrug-resistant Gram-negative bacterial infections, including infections caused by ESBL-producing Enterobacterales and select carbapenem-resistant pathogens. By combining the broad-spectrum antibacterial activity of cefepime with the B-lactamase inhibitory activity of tazobactam, WCK 4282 aims to enhance coverage against resistant organisms and provide an additional treatment option for severe hospital-acquired and complicated infections.

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Key Players, Market Leaders, and Emerging Companies

• Deerfield Management Company
• Cipla
• Merck
• Wockhardt, and others

Carbapenem-resistant Enterobacteriaceae (CRE) Infection Drug Updates

• In March 2026, Wockhardt received a favourable recommendation from CDSCO's Subject Expert Committee for marketing approval of Zidebactam/Cefepime (Zaynich) in Gram-negative infections, advancing the novel antibiotic toward DCGI approval for tackling MDR and XDR-resistant infections.
• In September 2025, Deerfield Management Company announced the sale of its portfolio company, Melinta Therapeutics, to CorMedix, Inc. Deerfield had acquired full private ownership of Melinta in 2020 through a financial restructuring and supported the company's growth by leveraging its operational, business development, data analytics, and market research capabilities to expand Melinta's anti-infective product portfolio.
• In May 2025, Cipla launched Plazomicin (ZEMDRI) in India for the treatment of cUTIs, including pyelonephritis, strengthening its anti-microbial resistance (AMR) portfolio and addressing rising multidrug-resistant and CRE infections.

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Market Outlook

The CRE Infection market is undergoing a significant transformation, moving beyond conventional therapies such as polymyxins, tigecycline, and aminoglycosides toward advanced B-lactam/B-lactamase inhibitor combinations and mechanism-driven antibacterial agents. The growing adoption of therapies such as ZERBAXA, RECARBRIO, VABOMERE, FETROJA, and XERAVA reflects a broader shift toward targeted antimicrobial therapies with enhanced activity against multidrug-resistant Gram-negative pathogens, improved safety profiles, and the potential to reduce reliance on older, more toxic treatment options. These advances underscore the increasing focus on overcoming B-lactamase-mediated resistance and restoring the utility of established antibiotic classes, thereby reshaping the competitive landscape of CRE treatment.

The pipeline continues to evolve with emerging therapies such as WCK-5222, WCK-4282, and WCK-6777 from Wockhardt Ltd., alongside other next-generation antimicrobial combinations targeting resistant Enterobacterales. These investigational therapies aim to address persistent unmet needs by expanding treatment options for multidrug-resistant and carbapenem-resistant infections while reducing dependence on legacy antibiotics. Among the 7MM, the United States represents the largest CRE infection market, driven by higher hospitalization rates, increasing antimicrobial resistance surveillance, greater access to advanced antibacterial therapies, favorable reimbursement environments, and more rapid adoption of newly approved treatments compared with the EU4, the United Kingdom, and Japan.

Overall, the introduction of differentiated antibacterial agents, expansion of combination therapies targeting resistant Gram-negative organisms, growing antimicrobial stewardship initiatives, improved diagnostic capabilities, and rising awareness regarding hospital-acquired infections are expected to drive steady growth in the 7MM CRE infection market from 2022-2036, creating significant commercial opportunities for both marketed therapies and emerging pipeline candidates.

• According to the estimates, the United States accounted for the largest share of the CRE Infection market in 2025. The total market size across the 7MM was approximately USD 300 million and is projected to grow further through 2036.
• The CRE infection market is evolving as treatment strategies shift from conventional toward advanced B-lactam/B-lactamase inhibitor combinations, with newer agents such as ZERBAXA, RECARBRIO, and VABOMERE, driving adoption due to enhanced activity against multidrug-resistant Gram-negative pathogens, improved clinical outcomes, and reduced nephrotoxicity compared with older therapies.
• The US leads the CRE market due to its high antimicrobial resistance burden, rapid adoption of novel antibiotics, and favorable reimbursement environment, while the EU and Japan are experiencing steady growth supported by enhanced surveillance, antimicrobial stewardship efforts, and increasing uptake of new anti-CRE therapies.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Carbapenem-resistant Enterobacteriaceae (CRE) Infection (2022-2036 Forecast)

The CRE infection market comprises polymyxins, B-lactam/B-lactamase inhibitor combinations, aminoglycosides, tetracycline derivatives, and emerging next-generation antibacterial therapies, each targeting distinct resistance mechanisms associated with CRE infections.

• Conventional antibiotic therapies: Agents such as colistin, polymyxin B, tigecycline, and aminoglycosides remain important salvage treatment options for CRE infections, particularly in severe hospital-acquired infections, although their use is often limited by nephrotoxicity, neurotoxicity, and rising resistance.
• B-lactam/B-lactamase inhibitor combinations: Therapies such as AVYCAZ, RECARBRIO, VABOMERE, and XACDURO have significantly improved CRE management by restoring antibacterial activity against resistant Gram-negative pathogens through inhibition of carbapenemases and other B-lactamases. These agents now represent a major advancement in targeted CRE treatment.
• Novel and next-generation antibacterial therapies: Emerging candidates such as WCK 5222, WCK 4282, and WCK 6777 are being developed to address multidrug-resistant and extensively drug-resistant Gram-negative infections through enhanced B-lactamase inhibition and improved antibacterial potency.
• Supportive and combination treatment approaches: Combination antibiotic regimens, infection-control strategies, rapid diagnostic tools, and antimicrobial stewardship programs remain essential for optimizing treatment outcomes, limiting resistance development, and reducing CRE-associated morbidity and mortality.

B-lactam/B-lactamase inhibitor combinations and emerging antibacterial therapies together define the core innovation landscape in CRE infections, with recently approved agents improving current treatment standards, while next-generation resistance-targeting therapies are expected to drive future market growth.

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the CRE infection market's uptake by drugs, patient uptake by therapy, and sales of each drug.

The uptake of therapies in CRE infections is expected to vary across conventional polymyxin- and aminoglycoside-based regimens, B-lactam/B-lactamase inhibitor combinations, and emerging next-generation antibacterial agents. Recently approved or increasingly adopted therapies such as ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam are anticipated to demonstrate moderate to high uptake, while newer agents, including cefiderocol and investigational anti-CRE therapies, are expected to witness progressive uptake, supported by improved efficacy against multidrug-resistant Gram-negative pathogens, reduced toxicity, and broader activity against carbapenemase-producing organisms. Their adoption is likely to be driven by the limitations of older treatment options, including nephrotoxicity associated with polymyxins, limited clinical efficacy, and rising antimicrobial resistance. In comparison, other novel antimicrobial combinations, bacteriophage-based therapies, and pathogen-targeted approaches are expected to experience gradual but steady uptake as clinical evidence expands, and these therapies become increasingly incorporated into antimicrobial stewardship programs and treatment guidelines for severe CRE infections across hospital and critical care settings.

Market Access and Reimbursement of CRE Infection

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Further details are provided in the final report....

Carbapenem-resistant Enterobacteriaceae (CRE) Infection Therapies Price Scenario & Trends

Pricing and analogue assessment of CRE Infection therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report....

Industry Experts and Physician Views for Carbapenem-resistant Enterobacteriaceae (CRE) Infection

To keep up with CRE market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the CRE infection emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in CRE, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the Harvard Medical School, University of Nottingham, and Japanese Red Cross Central Blood Institute, etc. were contacted. Their opinion helps understand and validate current and emerging CRE infection therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in IDA.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of CRE infection, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of CRE infection, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the CRE infection market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM CRE infection market.

Report Insights

• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Patient Population Forecast
• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Therapeutics Market Size
• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Pipeline Analysis
• Carbapenem-resistant Enterobacteriaceae (CRE) Infection Market Size and Trends
• Carbapenem-resistant Enterobacteriaceae (CRE) Infection Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year Forecast
• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Treatment Addressable Market (TAM)
• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Competitive Landscape
• Carbapenem-resistant Enterobacteriaceae (CRE) Infection Major Companies Insights
• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Price Trends and Analogue Assessment
• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Therapies Drug Adoption/Uptake
• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Therapies Peak Patient Share Analysis

Report Assessment

• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Current Treatment Practices
• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Unmet Needs
• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Clinical Development Analysis
• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Emerging Drugs Product Profiles
• Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Market Attractiveness
• Carbapenem-resistant Enterobacteriaceae (CRE) Infection Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the CRE Infection market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of CRE Infection?
• What are the disease risks, burdens, and unmet needs of CRE Infection? What will be the growth opportunities across the 7MM concerning the patient population with Carbapenem-resistant Enterobacteriaceae CRE Infection?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of CRE Infection? What are the current guidelines for treating CRE Infection in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the CRE Infection market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology

6. Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Market Overview at a Glance

• 6.1. Emerging Landscape Analysis (By Phase, Molecule Type, and RoA)
• 6.2. Market Share (%) Distribution of CRE infection by Therapies in the 7MM, in 2025
• 6.3. Market Share (%) Distribution of CRE infection by Therapies in the 7MM, in 2036

7. Disease Background and Overview of Carbapenem-resistant Enterobacteriaceae (CRE) Infection

• 7.1. Introduction
• 7.2. Enterobacteriaceae
• 7.3. Classification of Carbapenem-resistant Enterobacteriaceae
• 7.4. Risk and Spread of CRE Infection
• 7.5. Mechanism of Drug Resistance
• 7.6. Symptoms
• 7.7. Diagnosis of CRE
• 7.8. Guidelines

8. Treatment for Carbapenem-resistant Enterobacteriaceae (CRE) Infections

• 8.1. Guidelines

9. Epidemiology and Patient Population of Carbapenem-resistant Enterobacteriaceae (CRE) Infection

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total Incident Cases of CRE infection in the 7MM
• 9.4. The United States
  • 9.4.1. Total Incident Cases of Carbapenem-resistant Enterobacteriaceae (CRE) Infection in the US
  • 9.4.2. Type-specific Incident Cases of Carbapenem-resistant Enterobacteriaceae (CRE) Infection in the US
  • 9.4.3. Age-specific Incident cases of Carbapenem-resistant Enterobacteriaceae (CRE) Infection in the US
  • 9.4.4. Total treated Cases of Carbapenem-resistant Enterobacteriaceae (CRE) Infection in the US
• 9.5. EU4 and the UK
  • 9.5.1. Total Incident Cases of Carbapenem-resistant Enterobacteriaceae (CRE) Infection in EU4 and the UK
  • 9.5.2. Type-Specific Incident Cases of Carbapenem-resistant Enterobacteriaceae (CRE) Infection in EU4 and the UK
  • 9.5.3. Age-specific Incident cases of Carbapenem-resistant Enterobacteriaceae (CRE) Infection in EU4 and the UK
  • 9.5.4. Total treated Cases of Carbapenem-resistant Enterobacteriaceae (CRE) Infection in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Incident Cases of Carbapenem-resistant Enterobacteriaceae (CRE) Infection in Japan
  • 9.6.2. Type-specific Incident Cases of Carbapenem-resistant Enterobacteriaceae (CRE) Infection in Japan
  • 9.6.3. Age-specific Incident cases of Carbapenem-resistant Enterobacteriaceae (CRE) Infection in Japan
  • 9.6.4. Total treated Cases of Carbapenem-resistant Enterobacteriaceae (CRE) Infection in Japan

10. Patient Journey of Carbapenem-resistant Enterobacteriaceae (CRE) Infection

11. Marketed Therapies

• 11.1. Marketed Competitive Landscape of Carbapenem-resistant Enterobacteriaceae (CRE) Infection
• 11.2. Meropenem/Vaborbactam (Vabomere): Deerfield Management Company
  • 11.2.1. Drug Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Summary of Pivotal Trials
  • 11.2.5. Clinical Development
    • 11.2.5.1. Clinical Trial Information
  • 11.2.6. Analyst's Views
• 11.3. Plazomicin (Zemdri): Cipla
  • 11.3.1. Drug Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Summary of Pivotal Trials
  • 11.3.5. Clinical Development
    • 11.3.5.1. Clinical Trial Information
  • 11.3.6. Analyst's Views

12. Emerging Drugs

• 12.1. Emerging Competitive Landscape of Carbapenem-resistant Enterobacteriaceae (CRE) Infection
• 12.2. Zidebactam/Cefepime (WCK 5222): Wockhardt
  • 12.2.1. Drug Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
    • 12.2.3.1. Clinical Trials Information
  • 12.2.4. Analyst's Views
• 12.3. Cefepime/Tazobactam (WCK 4282): Wockhardt
  • 12.3.1. Drug Description
  • 12.3.2. Other Developmental Activities
  • 12.3.3. Clinical Development
    • 12.3.3.1. Clinical Trials Information
  • 12.3.4. Analyst's Views

13. Carbapenem-resistant Enterobacteriaceae (CRE) Infection: 7MM Analysis

• 13.1. Key Findings
• 13.2. Market Outlook of Carbapenem-resistant Enterobacteriaceae (CRE) Infection
• 13.3. Key Market Forecast Assumptions
  • 13.3.1. Cost Assumptions
  • 13.3.2. Pricing Trends
  • 13.3.3. Analogue Assessment
  • 13.3.4. Launch Year and Therapy Uptakes
• 13.4. Conjoint Analysis of Carbapenem-resistant Enterobacteriaceae (CRE) Infection
• 13.5. Total Market Size of CRE Infection in the 7MM
• 13.6. Total Market Size of CRE Infection by Therapies in the 7MM
• 13.7. The United States
  • 13.7.1. Total Market Size of CRE Infection in the United States
  • 13.7.2. Total Market Size of CRE Infection by Therapies in the United States
• 13.8. EU4 and the UK
  • 13.8.1. Total Market Size of CRE Infection in EU4 and the UK
  • 13.8.2. Total Market Size of CRE Infection by Therapies in EU4 and the UK
• 13.9. Japan
  • 13.9.1. Total Market Size of CRE Infection in Japan
  • 13.9.2. Total Market Size of CRE Infection by Therapies in Japan

14. Unmet Needs of Carbapenem-resistant Enterobacteriaceae (CRE) Infection

15. SWOT Analysis of Carbapenem-resistant Enterobacteriaceae (CRE) Infection

16. KOL Views of Carbapenem-resistant Enterobacteriaceae (CRE) Infection

17. Market Access and Reimbursement of Carbapenem-resistant Enterobacteriaceae (CRE) Infection

• 17.1. The United States
• 17.2. EU4 and the UK
  • 17.2.1. Germany
  • 17.2.2. France
  • 17.2.3. Italy
  • 17.2.4. Spain
  • 17.2.5. United Kingdom
• 17.3. Japan
• 17.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 17.5. Market Access and Reimbursement of CRE Infection Therapies

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight